CEL-SCI Corporation (NYSE American: CVM) is ready to discuss its Phase 3 head and neck cancer trial results after the Annual Shareholder Meeting. The study was featuring Multikine, investigational cancer immunotherapy known to have 14 natural human cytokines. The results indicate a significant production of 14.1% 5-year survival benefit (62.7% […]